Targeting human central nervous system protein kinases: An isoform selective p38αMAPK inhibitor that attenuates disease progression in Alzheimer's disease mouse models.
about
Targeting innate immunity for neurodegenerative disorders of the central nervous systemSelective Brain-Targeted Antagonism of p38 MAPKα Reduces Hippocampal IL-1β Levels and Improves Morris Water Maze Performance in Aged RatsNeuronal p38α mediates synaptic and cognitive dysfunction in an Alzheimer's mouse model by controlling β-amyloid production.ALS-linked FUS exerts a gain of toxic function involving aberrant p38 MAPK activation.p38α MAPK and Type I Inhibitors: Binding Site Analysis and Use of Target Ensembles in Virtual Screening.MW151 Inhibited IL-1β Levels after Traumatic Brain Injury with No Effect on Microglia Physiological Responses.Selective suppression of the α isoform of p38 MAPK rescues late-stage tau pathology.Protein misfolding in neurodegenerative diseases: implications and strategies.Efficient Binding of the NOS1AP C-Terminus to the nNOS PDZ Pocket Requires the Concerted Action of the PDZ Ligand Motif, the Internal ExF Site and Structural Integrity of an Independent ElementRetention of normal glia function by an isoform-selective protein kinase inhibitor drug candidate that modulates cytokine production and cognitive outcomes.Hippocampal metabotropic glutamate receptor long-term depression in health and disease: focus on mitogen-activated protein kinase pathways.Kinase targets in CNS drug discovery.p38 Mitogen activated protein kinase (MAPK): a new therapeutic target for reducing the risk of adverse pregnancy outcomes.Time-dependent reversal of synaptic plasticity induced by physiological concentrations of oligomeric Aβ42: an early index of Alzheimer's disease.Tau Proteins and Tauopathies in Alzheimer's Disease.Activation of EP2 receptor suppresses poly(I: C) and LPS-mediated inflammation in primary microglia and organotypic hippocampal slice cultures: Contributing role for MAPKs.A Comprehensive Structural Overview of p38α Mitogen-Activated Protein Kinase in Complex with ATP-Site and Non-ATP-Site Binders.SB203580 reverses memory deficits and depression-like behavior induced by microinjection of Aβ1-42 into hippocampus of mice.An exploratory clinical study of p38α kinase inhibition in Alzheimer's disease.Inhibiting p38 MAPK alpha rescues axonal retrograde transport defects in a mouse model of ALS.p38α MAPK signaling drives pharmacologically reversible brain and gastrointestinal phenotypes in the SERT Ala56 mouseGlobal Approaches to Understanding Protein Kinase FunctionsAn isoform-selective p38α mitogen-activated protein kinase inhibitor rescues early entorhinal cortex dysfunctions in a mouse model of Alzheimer's diseaseToward the Language OscillogenomeNeuronal MAP kinase p38α inhibits c-Jun N-terminal kinase to modulate anxiety-related behaviour
P2860
Q26744219-BAA257B1-FACA-429F-9E0A-20B93EE937B2Q28828716-713F49D7-8E91-4DA7-AC84-4FBA57DB3FD3Q30843406-D91BAF5B-3EB2-4F4C-9259-5E8C28617D86Q30849444-FA0F5EA6-FC0D-4FF2-AB8D-330A75A2F426Q35762844-6ED5E159-C248-4510-BD6A-B6071365ECC4Q35922026-62AA922A-79FC-44A5-B72B-0B3C442831C4Q37504904-734D284E-F301-4415-A21A-273466761BC8Q37697832-78D6578C-51E4-401D-B138-D616A532B790Q37699516-6B3478D1-D58D-4BD6-A98B-1A32CF92F4A2Q38708742-47892EB0-67E9-41F1-AC0D-2E56DDECE98CQ38753843-95DFBE9B-B69E-46FE-92FC-EB9C2552820AQ38760031-611330A5-5C3C-48A6-B160-D72C54895AF2Q38908783-E53545E9-F582-4A10-8D38-CCBFDEAA3708Q40991050-94CBC30E-C8DF-4FD9-975C-F2AA40394F45Q47233523-520E26BC-8D1F-40C3-98AD-D1FDAFDD79A7Q47309400-566C5B9B-3426-4A66-8D1A-0EE347F70FEBQ47324721-5BDA5594-0A9A-480B-AD27-844CAA7D1117Q48046432-EB91809F-ABF8-478D-B48F-79B5E55A17CBQ53397430-0814C5CE-53D8-42B1-ADB5-B458B103BA6DQ54978488-83ADD56E-81C8-4F52-9D2D-CA773067454AQ57295974-6CAD8A12-43D1-4DC5-BF5E-D08511A4533AQ57833109-A54384A5-851E-46F1-922E-994CF5D74F74Q58202794-E6267308-5753-4523-8202-F861B8105B90Q58574000-B8222F70-BDD5-47F5-973C-4C0AA4B324DEQ58700557-953FD5D3-09AB-448F-85B0-47872B1A3234
P2860
Targeting human central nervous system protein kinases: An isoform selective p38αMAPK inhibitor that attenuates disease progression in Alzheimer's disease mouse models.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Targeting human central nervou ...... heimer's disease mouse models.
@en
type
label
Targeting human central nervou ...... heimer's disease mouse models.
@en
prefLabel
Targeting human central nervou ...... heimer's disease mouse models.
@en
P2093
P2860
P50
P1476
Targeting human central nervou ...... zheimer's disease mouse models
@en
P2093
Agnieszka Staniszewski
Andrew F Teich
Faisal Saeed
James P Schavocky
Jeffrey C Pelletier
Linda J Van Eldik
Saktimayee M Roy
Scott J Webster
Valerie L Grum-Tokars
Wayne F Anderson
P2860
P304
P356
10.1021/ACSCHEMNEURO.5B00002
P577
2015-02-23T00:00:00Z